GLP-1 Drugs Market 2026: Size, Growth Forecasts, and the CDMOs Powering Supply

GLP-1 drugs have gone from a niche diabetes therapy to the fastest-growing category in pharmaceutical history and in 2026, the story is no longer just about demand. It’s about who can manufacture enough of them, fast enough, safely enough. According to Mordor Intelligence, the global GLP-1 agonists market is valued at USD 52.30 billion in 2026 and is projected to reach USD 97.45 billion by 2031, growing at a CAGR of 13.26%. This guide breaks down where the market stands today, which CDMOs and drugmakers are racing to add capacity, and what regulators, patents, and AI-driven pipelines mean for the next phase of growth.

What are GLP-1 agonists?

GLP-1 (glucagon-like peptide-1) receptor agonists are a class of medications that mimic a naturally occurring gut hormone involved in insulin secretion, appetite regulation, and blood sugar control. Originally developed to treat type 2 diabetes, they are now widely prescribed for obesity and weight management, and are under active investigation for cardiovascular disease, chronic kidney disease, and metabolic dysfunction-associated steatohepatitis (MASH).

Common GLP-1 drugs on the market today:

• Semaglutide — Ozempic and Rybelsus (diabetes), Wegovy (obesity, injectable and oral pill)
• Tirzepatide — Mounjaro (diabetes), Zepbound (obesity) — a dual GLP-1/GIP agonist
• Liraglutide — Victoza, Saxenda
• Dulaglutide — Trulicity
• Exenatide — Byetta, Bydureon
• Orforglipron (brand name Foundayo) — Eli Lilly’s oral small-molecule GLP-1, approved April 2026

GLP-1 drugs market size (2026)

According to Mordor Intelligence, the global Glucagon-like Peptide-1 (GLP-1) Agonists Market is valued at USD 52.30 billion in 2026 and is projected to grow at a CAGR of 13.26% to reach USD 97.45 billion by 2031.

Regional market share

North America contributed 41.13% of global revenue in 2025, while Asia-Pacific is projected to be the fastest-growing region, expanding at an 18.81% CAGR through 2031 as China, Japan, and India unlock large patient populations. Mordor Intelligence notes that with once-weekly semaglutide and tirzepatide exclusivity lasting until at least 2031, the market will likely remain a duopoly in premium markets, with only incremental erosion from value-tier competition rather than disruptive share shifts in the near term.

Latest News on GLP-1 drugs-

Oral GLP-1s: the 2026 shift

For most of GLP-1s’ commercial history, every approved product was an injectable. That changed in the past twelve months, and it matters for manufacturing as much as for patients:

• Wegovy pill (oral semaglutide): approved for weight management in late 2025 and launched in the U.S. in January 2026. Novo Nordisk announced in mid-2026 that prescriptions had topped 3 million just five months after launch.
• Foundayo (orforglipron), Eli Lilly: the first oral small-molecule GLP-1 receptor agonist, approved in April 2026. Unlike oral semaglutide (an oral peptide), orforglipron’s small-molecule chemistry means its supply chain resembles a standard API rather than a peptide process a meaningfully different manufacturing profile.

Industry estimates put the injectable/oral split at roughly 70% injectable to 30% oral for the foreseeable future, according to Stevanato Group’s investor commentary, even as oral formats broaden the patient base.

From the PharmaSource Podcast

“Capacity isn’t the biggest gap. It’s people. And nobody’s talking about it.” — Steven Kaufman, combination-product strategy advisor, on why fill/finish capacity remains tight even as billions pour into new facilities. GLP-1 manufacturers have drawn skilled workers out of the broader CDMO ecosystem for two straight years, and as CDMOs take on more device assembly, primary-container sourcing, and serialization work for combination products, that talent gap is becoming as consequential as square footage. Listen to the full episode →

Regulatory pressure: FDA’s 2026 crackdown

As GLP-1 demand outpaced approved supply between 2022 and 2025, compounded and counterfeit versions proliferated and FDA enforcement has intensified sharply in response:

• FDA’s Center for Drug Evaluation and Research issued 303 warning letters to drug and biologics manufacturers in fiscal year 2025, a 59% increase from 190 in FY2024, according to an analysis of inspection and enforcement trends.
• In September 2025, FDA introduced a “Green List” import alert (66-80) restricting entry for foreign GLP-1 API manufacturers that haven’t demonstrated GMP compliance.
• FDA has proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List, which would significantly curtail large-scale compounding of these drugs, per BioPharma Dive.
• Despite the crackdown, a recent Gallup survey cited by BioPharma Dive found that nearly 1 in 5 Americans taking a GLP-1 weight-loss drug (about 20%) are still using a non-FDA-approved version — even as total U.S. GLP-1 usage has roughly quadrupled in two years.

From the PharmaSource Newsroom

Quality failures at contract facilities are increasingly being treated as the sponsor’s problem too. A March 2026 FDA warning letter to ABR Pharma made explicit that the agency views contract manufacturing sites as “extensions of the manufacturer’s own facility” — meaning CDMO and third-party lab quality lapses now carry direct consequences for the sponsors that hired them. Read the full analysis →

Patent cliff and biosimilar timeline

Because semaglutide and tirzepatide are peptides rather than small-molecule chemicals, their path to generic competition is longer and more complex than a typical drug — and estimates of when that competition arrives vary meaningfully by source, so treat any single date with caution:

• Semaglutide (Ozempic/Wegovy): U.S. composition-of-matter patent expiration is most commonly estimated around December 2031, though some analyses put realistic biosimilar market entry as late as 2032–2033. Outside the U.S., semaglutide’s composition patent has already expired in India, China, Canada, Brazil, and Turkey as of April 2026, per IQVIA.
• Tirzepatide (Mounjaro/Zepbound): Eli Lilly’s core U.S. patent runs to January 2036, with some analysts not expecting meaningful price competition until 2038–2040.
• Liraglutide (Victoza): already off-patent the FDA approved the first generic GLP-1 drug, generic liraglutide, in December 2024.
• Whether semaglutide and tirzepatide ultimately follow the small-molecule generic (ANDA) pathway or the biosimilar (351(k) biologics) pathway differs by regulator the FDA currently treats peptides under 40 amino acids as eligible for the generic pathway, while several other markets classify them as biologics requiring full biosimilar review.

Next-generation pipeline

The next wave of GLP-1-class therapies is moving through late-stage trials, aiming to improve on efficacy, dosing frequency, or convenience:

• Retatrutide (Eli Lilly) – a triple agonist targeting GIP, GLP-1, and glucagon receptors has shown more than 28% weight loss in Phase 3 trials, the highest reported to date in the class. A regulatory filing is expected in late 2026, with approval unlikely before 2027–2028.
• MariTide (Amgen) – a monthly antibody-peptide conjugate produced 16–20% weight loss in Phase 2, with weight loss notably persisting after dosing stopped.
• Aleniglipron/GSBR-1290 (Structure Therapeutics) – an oral small-molecule GLP-1 is advancing into Phase 3 in the second half of 2026, alongside an emerging pipeline of amylin and multi-receptor combination candidates.

AI’s growing role in GLP-1 drug discovery

Artificial intelligence is increasingly shaping how the next generation of GLP-1-class therapies gets designed, not just how existing ones get marketed:

• Researchers have used AI-driven de novo peptide design to generate thousands of candidate GLP-1 receptor agonist sequences computationally, screening for stability and potency before any wet-lab synthesis — one published approach reported lead candidates with roughly triple the half-life of semaglutide in preclinical models.
• Machine-learning-guided QSAR platforms are being used to develop GLP-1 receptor agonists with improved physicochemical stability, a longstanding bottleneck in peptide drug development, according to research published in the Journal of Medicinal Chemistry.
• Structure Therapeutics’ entire oral small-molecule pipeline is built on a structure-based computational drug discovery platform designed to move beyond the scalability limits of traditional biologic and peptide manufacturing.
• Medical researchers recognized at the 2026 AMA Research Challenge for using machine learning to design triple-agonist peptides that target GLP-1, glucagon, and GIP receptors simultaneously — illustrating how academic AI research is feeding directly into the next-generation pipeline.

For CDMOs and sponsors, the practical implication is a shorter, more predictable design phase — but one that still funnels into the same finite pool of sterile fill-finish and peptide synthesis capacity described above.

Market dynamics to watch

• Medicare coverage expansion: starting July 1, 2026, millions of Medicare-eligible seniors gained access to GLP-1 drugs for weight loss at roughly $50/month under new coverage agreements a significant new demand driver that both Novo Nordisk and Eli Lilly are actively positioning for.
• “Most favored nation” pricing deals: both companies struck pricing agreements with the Trump administration in November 2025 to reduce list prices for obesity and diabetes drugs, which analysts expect to pressure near-term revenue per prescription while expanding volume.
• Novo Nordisk vs. Eli Lilly divergence: the two market leaders are on visibly different trajectories in 2026 Lilly’s Cardiometabolic Health segment generated approximately $15.8 billion in Q1 2026 revenue, while Novo Nordisk’s Diabetes and Obesity Care segment reported DKK 91.4 billion (~$14.2 billion) in the same period, per Yahoo Finance. Novo underwent a CEO transition in 2025 amid the shift in competitive momentum.

Expert Insight: Novo Nordisk’s CEO on the competitive gap

At JPM26, Novo Nordisk CEO Maziar Doustdar candidly acknowledged the company’s “difficult 2025” as Eli Lilly pulled ahead in the obesity race, while also reframing the scale of opportunity still ahead: “us and Lilly combined probably have 10 [million or] 15 million patients. What about the other 85 million? We need to get to them.” Doustdar signaled Novo will refocus on its diabetes-and-obesity “DNA” rather than rushing into adjacent disease areas. Read the full interview →

Key market players

• Novo Nordisk
• Eli Lilly and Company
• AstraZeneca
• Sanofi
• Pfizer
• Boehringer Ingelheim
• Roche
• Merck
• Amneal Pharmaceuticals
• Ascendis Pharma
• Viking Therapeutics
• Innovent Biologics
• Hansoh Pharma
• Hanmi Pharmaceutical
• Tonghua Dongbao Pharmaceutical
• D&D Pharmatech
• Teva Pharmaceutical Industries
• Glenmark Pharmaceuticals

Restraining factors

• Patent litigation and IP thickets — Novo Nordisk holds over 150 granted U.S. patents related to semaglutide alone, extending exclusivity well past the “headline” expiration date and creating years of legal uncertainty for would-be generic/biosimilar entrants.
• Compounding backlash and regulatory tightening — the FDA’s Green List import alert and proposed 503B Bulks List exclusions directly threaten the compounded-drug segment that has served price-sensitive patients during the shortage years.
• Talent shortages — GLP-1 manufacturers have pulled skilled workers from across the broader CDMO ecosystem for two consecutive years, constraining how fast new capacity can actually be commissioned, not just built.
• Tariff and reshoring cost pressure — U.S. reshoring incentives are reshaping sourcing decisions away from established Asian peptide-API suppliers, adding cost and requalification timelines even where capacity exists.
• Pricing pressure — “most favored nation” agreements and expanding Medicare coverage are expected to compress per-prescription revenue even as volumes grow.